Hongri Pharmaceutical: Announcement on the company and Lanzhou Foci Pharmaceutical Co., Ltd. jointly providing guarantee for the company’s controlling subsidiary, Gansu Foci Hongri Pharmaceutical Co., Ltd.
Tianjin Hongri Pharmaceutical Co., Ltd. Securities code: 300026 Securities abbreviation: Hongri Pharmaceutical Announcement number: 2026-010
Tianjin Hongri Pharmaceutical Co., Ltd.
About the Company and Lanzhou Foci Pharmaceutical Co., Ltd.
Together they are the company’s controlling subsidiary, Gansu Foci Hongri Pharmaceutical Co., Ltd.
Announcement of Guarantee
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Special tips:
As of the disclosure date of this announcement, the total amount of guarantees provided by the company, subsidiaries and subsidiary companies (including this guarantee) is RMB 1,360.20 million, accounting for 15.74% of the company's latest audited net assets. This guarantee is a guarantee provided by Sun Company within the scope of the company's consolidated statements. Sun Company's asset-liability ratio exceeds 70%, but the guarantee amount does not exceed 50% of the company's latest audited net assets. Investors are asked to pay full attention to the guarantee risks.
Tianjin Hongri Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the sixth meeting of the ninth board of directors on March 20, 2026, and reviewed and approved the "Proposal on the Company and Lanzhou Foci Pharmaceutical Co., Ltd. to jointly provide guarantees for the company's controlling subsidiary, Gansu Foci Hongri Pharmaceutical Co., Ltd.". The proposal has been reviewed and approved at a special meeting of the company's independent directors, and the matter still needs to be submitted to the company's shareholders' meeting for review and approval. The relevant information is now announced as follows:
1. Overview of guarantee situation
(1) On March 29, 2023, the company held the seventh meeting of the eighth board of directors, and reviewed and approved the "Proposal on the Company and Lanzhou Foci Pharmaceutical Co., Ltd. to jointly provide guarantees for the company's controlled subsidiary Gansu Foci Hongri Pharmaceutical Co., Ltd." The company applied for a working capital loan of RMB 60 million from Weiyuan County Rural Credit Cooperative Cooperative for Gansu Foci Hongri Pharmaceutical Co., Ltd. (hereinafter referred to as "Foci Hongri"), with a loan term of 3 years, to supplement working capital. The company provides a joint liability guarantee of RMB 33.6 million for Foci Hongri with a 56% equity ratio. Foci Pharmaceutical provides a joint liability guarantee of RMB 26.40 million for Foci Hongri with a equity ratio of 44%. The guarantee period is 3 years. For details, please refer to the China Securities Regulatory Commission’s Guidelines
The GEM information disclosure website (www.cninfo.com.cn) established by Tianjin Hongri Pharmaceutical Co., Ltd. is "Announcement on the Company and Lanzhou Foci Pharmaceutical Co., Ltd. jointly providing guarantee for the company's controlling subsidiary, Gansu Foci Hongri Pharmaceutical Co., Ltd." (Announcement Number: 2023-017). As of the reporting date, the "Guarantee Contract" related to this guarantee matter has been signed, and the Foci Hongri working capital loan has been used in total of RMB 54 million.
(2) In view of the above guarantee arrangement, in order to further reduce financing costs and supplement working capital, Foci Hongri has jointly discussed and negotiated with shareholders of Lanzhou Foci Pharmaceutical Co., Ltd. (hereinafter referred to as "Foci Pharmaceutical") and reached an agreement through communication with multiple parties: Foci Hongri plans to apply for a working capital loan of 60 million yuan from the Lanzhou Branch of China CITIC Bank Co., Ltd. with a loan term of 2 years, which will be used to return the Weiyuan County Rural Credit Cooperative Union loan and supplement working capital. The company provided a joint liability guarantee of RMB 33.6 million for Foci Hongri with a 56% equity ratio, and Foci Pharmaceutical provided a joint liability guarantee of RMB 26.40 million for Foci Hongri with a equity ratio of 44%. The guarantee period is 2 years.
2. Estimated specific situation of guarantee amount
Guarantee Guaranteed Party New Guarantee Amount So Far Newly Added This Time
Holding shares with the guaranteed party The most recent share of the listed company Is it related to the guarantor Guaranteed party Guarantee balance Guarantee amount
Party relationship Share ratio Assets and liabilities Company’s latest joint guarantee (10,000 yuan) (10,000 yuan)
Example rate Net asset ratio
Gansu Foci Hongri Controlling Sun
Hongri Pharmaceutical 56% 73.05% 10,008.58 3,360.00 0.39% No Pharmaceutical Co., Ltd.
3. Basic information of the guaranteed person
Gansu Foci Hongri Pharmaceutical Co., Ltd.
Date of establishment: June 10, 2015
Registration location: Weiyuan Park, Industrial Concentration Zone, Weiyuan County, Dingxi City, Gansu Province
Legal representative: Wang Kai
Registered capital: one hundred and eighty-two hundred and fifty thousand yuan
Business scope: planting, breeding, acquisition, sales, testing and inspection of Chinese medicinal materials, planting technology research and development, promotion, transfer, service, consultation; medicinal material logistics, warehousing management; production and processing (cleaning, cutting, frying, roasting, steaming, boiling, forging, and water-cooking of Chinese herbal medicine pieces (toxic pieces, direct oral pieces)) Fly) and sales; production and sales of granules (traditional Chinese medicine formula granules) and tablets; production, processing, acquisition, and sales of agricultural and sideline products; production and sales of herbal teas, alternative teas, medicinal and food homologous health products, and plant extracts (projects that require approval according to law can only be carried out with the approval of relevant departments)
Whether he is the person subject to execution for breach of trust: No
Main financial data of Tianjin Hongri Pharmaceutical Co., Ltd.:
Unit: Ten thousand yuan project 2024-12-31 2025-09-30 project 2024-12-31 2025-09-30
Total assets 42,700.14 39,732.18 Total liabilities 31,307.41 29,023.13
Owner’s equity 11,392.73 10,709.05 Asset-liability ratio 73.32% 73.05%
—— 2024 January to September 2025 —— 2024 January to September 2025 Operating income 14,499.64 9,053.69 Net profit -2,562.91 -683.68
Note: The above financial data for the third quarter of 2025 are unaudited.
4. Main contents of the guarantee agreement
According to the accounting statement data provided by the guaranteed party, the asset-liability ratio in the latest period exceeded 70%. As of the reporting date, the "Guarantee Contract" related to this guarantee has not yet been signed. The specific guarantee content shall be subject to the actual signed contract and shall take effect after being reviewed and approved by the company's shareholders' meeting and reviewed, approved, signed and sealed by the internal agencies of other parties. If changes occur after the above guarantee matters are disclosed, the company will promptly disclose corresponding progress announcements.
5. Deliberation opinions of the special meeting of independent directors
After deliberation at a special meeting of the company's independent directors, all independent directors believed that in order to further reduce financing costs and supplement liquidity, the company's controlling subsidiary Foci Hongri has fulfilled the necessary approval procedures for this guarantee and complied with the relevant regulations and rules of the China Securities Regulatory Commission and the Shenzhen Stock Exchange. It is agreed that Foci Hongri plans to apply for a working capital loan of 60 million yuan from China CITIC Bank Co., Ltd. Lanzhou Branch with a loan term of 2 years, which will be used to repay the Weiyuan County Rural Credit Cooperative Union loan and supplement working capital. The company and Foci Pharmaceutical provide a joint and several liability guarantee based on the equity ratio of Foci Hongri, with a guarantee period of 2 years. And agreed to submit the matter to the sixth meeting of the company's ninth board of directors for review.
6. Opinions of the Board of Directors
The board of directors believes that this guarantee is a guarantee provided by the subsidiary company within the scope of the company's consolidated statements. The financial risk of the company's controlling subsidiary, Foci Red Japan, is within the company's controllable range and is conducive to the company's long-term development. The board of directors agreed that the company and Foci Pharmaceuticals will jointly plan to apply for a working capital loan of 60 million yuan from the Lanzhou Branch of China CITIC Bank Co., Ltd., with a term of 2 years, for Foci Hongri, the company's controlling subsidiary company, with a loan term of 2 years, which will be used to repay the Weiyuan County Rural Credit Cooperative Union loan and supplement working capital. The company provides Foci Hongri with a joint liability guarantee of RMB 33.60 million corresponding to a 56% equity ratio. Foci Pharmaceutical provides a joint liability guarantee of RMB 26.40 million corresponding to a 44% equity ratio for Foci Hongri. The guarantee period is 2
Tianjin Hongri Pharmaceutical Co., Ltd., and authorized the company’s management to handle the above-mentioned related matters.
7. Cumulative number of external guarantees and number of overdue guarantees
As of the disclosure date of this announcement, the total amount of guarantees provided by the company, subsidiaries and subsidiary companies (including this guarantee) is RMB 1,360.20 million, all of which are guarantees provided by subsidiaries and subsidiary companies within the scope of the company's consolidated statements, accounting for 15.74% of the company's latest audited net assets. The company and its subsidiaries have no overdue external guarantees, nor have they provided guarantees to shareholders, actual controllers and their related parties.
8. Documents for reference
(1) Resolution of the sixth meeting of the company’s ninth board of directors;
(2) Documents proving the performance of the duties of the special committee of independent directors.
Announcement is hereby made.
Board of Directors of Tianjin Hongri Pharmaceutical Co., Ltd.
March 20, 2026